Rationale and design of the RIACT–study: a multi-center placebo controlled double blind study to test the efficacy of RItuximab in Acute Cellular tubulointerstitial rejection with B-cell infiltrates in renal Transplant patients: study protocol for a randomized controlled trial

Rationale and design of the RIACT–study: a multi-center placebo controlled double blind study to test the efficacy of RItuximab in Acute Cellular tubulointerstitial rejection with B-cell infiltrates in renal Transplant patients: study protocol for a randomized controlled trial

<p>Abstract</p> <p>Background</p> <p>Acute kidney allograft rejection is a major cause for declining graft function and has a negative impact on the long-term graft survival. The majority (90%) of acute rejections are T-cell mediated and, therefore, the anti-rejection t...

Full description

Bibliographic Details
Main Authors: Schiffer Lena, Schiffer Mario, Merkel Saskia, Schwarz Anke, Mengel Michael, Jürgens Christopher, Schroeder Christoph, Zoerner Alexander A, Püllmann Kerstin, Bröcker Verena, Becker Jan U, Dämmrich Maximilian E, Träder Jana, Großhennig Anika, Biertz Frank, Haller Hermann, Koch Armin, Gwinner Wilfried
Format: Article
Language:English
Published: BMC 2012-10-01
Series:Trials
Subjects:
Cellular kidney allograft rejection
B-cells
Rituximab
Online Access:http://www.trialsjournal.com/content/13/1/199

Internet

http://www.trialsjournal.com/content/13/1/199

Similar Items